Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Running, not enrolling · Phase 2

Conditions studied: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7

In brief

This clinical trial studies combination chemotherapy, radiation therapy, and bevacizumab in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, work in different ways to stop the growth of \[cancer/tumor\] cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving more than one drug (combination chemotherapy) together with radiation therapy and bevacizumab may kill more tumor cells.

Key facts

Study ID

NCT00334815

Run by

National Cancer Institute (NCI)

People needed

29

Starts

2006-06-15

Expected to finish

2027-02-22

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed single, primary, bronchogenic, non-small cell lung cancer (NSCLC)
• Newly diagnosed disease
• Unresectable disease
• No more than 1 parenchymal lesions on same or opposite sides of the lungs
• Meets 1 of the following stage criteria:
• Stage IIIA (N2) disease meeting the following criteria:
• N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan or x-ray so that the patient is not a candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection
• N2 status must be documented by ≥ 1 of the following methods:
• Histologically or cytologically confirmed N2 disease by exploratory thoracotomy, thoracoscopy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle biopsy (WNB), fine needle aspiration (FNA) under bronchoscopic or CT guidance, or any other method
• Node positive by fludeoxyglucose-positron emission tomography (FDG-PET) scan
• Nodes > 3 cm on CT scan
• Paralyzed left true vocal cord with separate left lung primary distinct from anterior-posterior window nodes on CT scan
• Stage IIIB disease meeting ≥ 1 of the following criteria:
• Histologically or radiographically confirmed positive N3 nodes*, documented by ≥ 1 of the following methods:
• FNA, core needle biopsy (CNB), or excisional biopsy of supraclavicular N3 nodes
• Biopsy of contralateral mediastinal N3 nodes by mediastinoscopy, mediastinotomy, or thoracotomy
• FNA, CNB, or WNB under CT or bronchoscopic fluoroscopic guidance of enlarged contralateral N3 mediastinal nodes
• Contralateral mediastinal nodes > 3 cm on CT scan
• Node positivity by FDG-PET scan
• Right-sided primary with paralyzed left true vocal cord
• T4 lesions of any size that invade the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina, documented by ≥ 1 of the following methods:
• Written documentation of type of T4 extent if patient had a prior exploratory thoracotomy or thoracoscopy
• T4 involvement of the trachea or carina by direct bronchoscopic visualization
• T4 involvement of the heart, esophagus, aorta, or vertebral body by CT scan, MRI, or transesophageal ultrasound
• T4 involvement of the mediastinum by CT scan or MRI if, in the absence of the above organ involvement, there is soft tissue extension directly into the mediastinal space**

Where it is running

• Saint Bernards Regional Medical Center — Jonesboro, Arkansas, United States
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Highlands Oncology Group - Rogers — Rogers, Arkansas, United States
• USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Fremont - Rideout Cancer Center — Marysville, California, United States
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California, United States
• University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
• Providence Santa Rosa Memorial Hospital — Santa Rosa, California, United States
• Gene Upshaw Memorial Tahoe Forest Cancer Center — Truckee, California, United States
• Northbay Cancer Center — Vacaville, California, United States
• Rocky Mountain Regional VA Medical Center — Aurora, Colorado, United States
• UCHealth University of Colorado Hospital — Aurora, Colorado, United States
• Denver Health Medical Center — Denver, Colorado, United States
• Shaw Cancer Center — Edwards, Colorado, United States
• Valley View Hospital Cancer Center — Glenwood Springs, Colorado, United States
• Montrose Memorial Hospital — Montrose, Colorado, United States
• Cancer Centers of Central Florida PA — Leesburg, Florida, United States
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Edward Hospital/Cancer Center — Naperville, Illinois, United States
• HaysMed — Hays, Kansas, United States
• Hutchinson Regional Medical Center — Hutchinson, Kansas, United States
• University of Kansas Cancer Center — Kansas City, Kansas, United States
• Olathe Cancer Center — Olathe, Kansas, United States
• Providence Hospital — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.